Gut Microbiota Dysbiosis in Opioid Use Disorders: Implications for Clinical Symptoms and Relapse Rate.
Launched by ASSIUT UNIVERSITY · Jan 27, 2024
Trial Information
Current as of May 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the bacteria in the gut (called gut microbiota) may affect people who are dealing with opioid use disorders. The researchers want to understand if the types and amounts of bacteria in the gut can relate to symptoms experienced by patients and their chances of relapse, which means going back to using opioids after trying to stop. This study will involve male patients in Egypt who are experiencing withdrawal symptoms for the first time.
To participate, individuals need to have a confirmed diagnosis of substance misuse and must be facing withdrawal symptoms. However, those with certain conditions, like an IQ below 70 or any gastrointestinal diseases, will not be eligible. Since the trial is not yet recruiting, details about what participants can expect will be shared once the study begins. Overall, this research could help improve treatment options for those struggling with opioid dependence by focusing on how gut health might play a role in recovery.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinical and laboratory diagnosis of substance missuse.
- • 2. Must be encountering withdrawal symptoms for the first time.
- Exclusion Criteria:
- • 1. An intelligence quotient (IQ) below 70.
- • 2. Gastrointestinal diseases.
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alaa El-Din Darwish Othman, professor
Study Chair
assiutbird25@aun.edu.eg
GeLLan Karamallah Ramadan, doctor
Study Director
gillankaram@aun.edu.eg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported